MANKIND PHARMA LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,167 INR | -0.30% |
|
+1.95% | +9.31% |
| Jun. 03 | Mankind Pharma Limited Receives Order from Office of Superintendent of Central Tax, Bholakpur, Telangana | CI |
| May. 30 | Advent International Receives 6-7 Bids for Bharat Serums | CI |
| Sales 2024 | 103B 1.24B | Sales 2025 * | 116B 1.39B | Capitalization | 868B 10.39B |
|---|---|---|---|---|---|
| Net income 2024 | 19.13B 229M | Net income 2025 * | 22.14B 265M | EV / Sales 2024 | 8.92 x |
| Net cash position 2024 * | 25.25B 302M | Net cash position 2025 * | 40.68B 487M | EV / Sales 2025 * | 7.11 x |
| P/E ratio 2024 |
48.3
x | P/E ratio 2025 * |
39.2
x | Employees | 18,468 |
| Yield 2024 * |
0.29% | Yield 2025 * |
0.4% | Free-Float | 19.92% |
More Fundamentals
* Assessed data
More news
Latest transcript on Mankind Pharma Limited
More recommendations
| 1 day | -0.30% | ||
| 1 week | +1.95% | ||
| Current month | +1.27% | ||
| 1 month | -3.12% | ||
| 3 months | +0.59% | ||
| 6 months | +10.97% | ||
| Current year | +9.31% |
1 week
2 108.75
2 198.00
1 month
1 931.352 299.00
Current year
1 931.352 490.00
1 year
1 469.002 490.00
3 years
1 242.002 490.00
5 years
1 242.002 490.00
10 years
1 242.002 490.00
| Managers | Title | Age | Since |
|---|---|---|---|
Sheetal Arora
CEO | Chief Executive Officer | 48 | 07-09-20 |
Ashutosh Dhawan
DFI | Director of Finance/CFO | 55 | 16-06-16 |
Pradeep Chugh
CMP | Compliance Officer | - | 16-09-22 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Vivek Kalra
BRD | Director/Board Member | 60 | 22-07-31 |
Vijaya Sampath
BRD | Director/Board Member | 71 | 22-07-31 |
Surendra Lunia
BRD | Director/Board Member | 61 | 15-02-18 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-11 | 2,167 | -0.30% | 300,668 |
| 24-06-10 | 2,174 | +2.16% | 544,770 |
| 24-06-07 | 2,128 | -1.34% | 1,901,440 |
| 24-06-06 | 2,156 | +0.02% | 240,944 |
| 24-06-05 | 2,156 | +2.85% | 410,647 |
Delayed Quote NSE India S.E., June 11, 2024 at 07:40 am EDT
More quotes
Mankind Pharma Limited is an India-based pharmaceutical company. The Company is engaged in developing, manufacturing, and marketing a diverse range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products. The Company offers exceptional healthcare solutions for a wide range of healthcare needs with a diverse portfolio that includes anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/ central nervous system (CNS), vitamins, minerals and nutrients and respiratory therapies. Its portfolio of brands includes Nurokind, Telmikind, Manforce (Rx), Gudcef, Moxikind, Amlokind, Glimestar, Asthakind, Codistar, Candiforce, Mahacef, Dydroboon, Cefakind, Zenflox, Monticope, Dynaglipt, and others. The Company's subsidiaries include Lifestar Pharma Private Limited, Magnet Labs Private Limited, Broadway Hospitality Services Private Limited, Jaspack Industries Private Limited, and others.
Sector
Pharmaceuticals
Calendar
2024-07-30
- Q1 2025 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
14
Last Close Price
2,167
INR
Average target price
2,267
INR
Spread / Average Target
+4.61%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +9.31% | 10.42B | |
| +48.53% | 779B | |
| +40.67% | 631B | |
| -6.37% | 354B | |
| +20.93% | 333B | |
| +8.21% | 301B | |
| +16.75% | 249B | |
| -1.19% | 216B | |
| +10.85% | 214B | |
| +4.40% | 163B |
- Stock Market
- Equities
- MANKIND Stock
